A Practical Guide for Cardiologists to the Pharmacological Treatment of Patients with Type 2 Diabetes and Cardiovascular Disease
Patients with type 2 diabetes are at increased cardiovascular risk. Until recently, reductions in HbA1c and the use of specific glucose-lowering agents have not had a clear, reproducible benefit in reducing the incidence of cardiovascular disease. However, over the past 5 years, members of two categ...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Radcliffe Medical Media
2021-03-01
|
| Series: | European Cardiology Review |
| Online Access: | https://www.ecrjournal.com/articleindex/ecr.2020.01.R1 |
| _version_ | 1797200044455100416 |
|---|---|
| author | Tariq Ahmad Ralph J Riello Silvio E Inzucchi |
| author_facet | Tariq Ahmad Ralph J Riello Silvio E Inzucchi |
| author_sort | Tariq Ahmad |
| collection | DOAJ |
| description | Patients with type 2 diabetes are at increased cardiovascular risk. Until recently, reductions in HbA1c and the use of specific glucose-lowering agents have not had a clear, reproducible benefit in reducing the incidence of cardiovascular disease. However, over the past 5 years, members of two categories of diabetes medications, sodium–glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists, have been associated with improved rates of major adverse cardiovascular events when used in high-risk type 2 diabetes patients. Importantly, these effects are not necessarily linked to these agents’ effects on HbA1c. Sodium–glucose cotransporter 2 inhibitors have also been associated with reductions in heart failure hospitalization, a benefit that appears to extend to individuals without diabetes with established heart failure. Cardiovascular specialists should become familiar with these emerging data and be prepared to implement corresponding strategies in their practice to improve the cardiovascular outcomes of their patients. Recent clinical trial data and the changing landscape of corresponding professional guidelines are reviewed. Practical recommendations for safe prescribing of these anti-diabetes drugs are provided. |
| first_indexed | 2024-03-07T17:40:51Z |
| format | Article |
| id | doaj.art-5a91fa8d33ae45ea8b5afd48cb104e34 |
| institution | Directory Open Access Journal |
| issn | 1758-3756 1758-3764 |
| language | English |
| last_indexed | 2024-04-24T07:25:23Z |
| publishDate | 2021-03-01 |
| publisher | Radcliffe Medical Media |
| record_format | Article |
| series | European Cardiology Review |
| spelling | doaj.art-5a91fa8d33ae45ea8b5afd48cb104e342024-04-20T16:02:08ZengRadcliffe Medical MediaEuropean Cardiology Review1758-37561758-37642021-03-011610.15420/ecr.2020.01.R1A Practical Guide for Cardiologists to the Pharmacological Treatment of Patients with Type 2 Diabetes and Cardiovascular DiseaseTariq Ahmad0Ralph J Riello1Silvio E Inzucchi2Section of Cardiovascular Medicine, Yale University School of Medicine, New Haven, CT, USSection of Cardiovascular Medicine, Yale University School of Medicine, New Haven, CT, USSection of Endocrinology, Yale University School of Medicine, New Haven, CT, USPatients with type 2 diabetes are at increased cardiovascular risk. Until recently, reductions in HbA1c and the use of specific glucose-lowering agents have not had a clear, reproducible benefit in reducing the incidence of cardiovascular disease. However, over the past 5 years, members of two categories of diabetes medications, sodium–glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists, have been associated with improved rates of major adverse cardiovascular events when used in high-risk type 2 diabetes patients. Importantly, these effects are not necessarily linked to these agents’ effects on HbA1c. Sodium–glucose cotransporter 2 inhibitors have also been associated with reductions in heart failure hospitalization, a benefit that appears to extend to individuals without diabetes with established heart failure. Cardiovascular specialists should become familiar with these emerging data and be prepared to implement corresponding strategies in their practice to improve the cardiovascular outcomes of their patients. Recent clinical trial data and the changing landscape of corresponding professional guidelines are reviewed. Practical recommendations for safe prescribing of these anti-diabetes drugs are provided.https://www.ecrjournal.com/articleindex/ecr.2020.01.R1 |
| spellingShingle | Tariq Ahmad Ralph J Riello Silvio E Inzucchi A Practical Guide for Cardiologists to the Pharmacological Treatment of Patients with Type 2 Diabetes and Cardiovascular Disease European Cardiology Review |
| title | A Practical Guide for Cardiologists to the Pharmacological Treatment of Patients with Type 2 Diabetes and Cardiovascular Disease |
| title_full | A Practical Guide for Cardiologists to the Pharmacological Treatment of Patients with Type 2 Diabetes and Cardiovascular Disease |
| title_fullStr | A Practical Guide for Cardiologists to the Pharmacological Treatment of Patients with Type 2 Diabetes and Cardiovascular Disease |
| title_full_unstemmed | A Practical Guide for Cardiologists to the Pharmacological Treatment of Patients with Type 2 Diabetes and Cardiovascular Disease |
| title_short | A Practical Guide for Cardiologists to the Pharmacological Treatment of Patients with Type 2 Diabetes and Cardiovascular Disease |
| title_sort | practical guide for cardiologists to the pharmacological treatment of patients with type 2 diabetes and cardiovascular disease |
| url | https://www.ecrjournal.com/articleindex/ecr.2020.01.R1 |
| work_keys_str_mv | AT tariqahmad apracticalguideforcardiologiststothepharmacologicaltreatmentofpatientswithtype2diabetesandcardiovasculardisease AT ralphjriello apracticalguideforcardiologiststothepharmacologicaltreatmentofpatientswithtype2diabetesandcardiovasculardisease AT silvioeinzucchi apracticalguideforcardiologiststothepharmacologicaltreatmentofpatientswithtype2diabetesandcardiovasculardisease AT tariqahmad practicalguideforcardiologiststothepharmacologicaltreatmentofpatientswithtype2diabetesandcardiovasculardisease AT ralphjriello practicalguideforcardiologiststothepharmacologicaltreatmentofpatientswithtype2diabetesandcardiovasculardisease AT silvioeinzucchi practicalguideforcardiologiststothepharmacologicaltreatmentofpatientswithtype2diabetesandcardiovasculardisease |